Fig. 7

AnxA6 level negatively correlates with SENP1 expression in HCC tissues. (A) Representative immunohistochemical staining and quantitative results of AnxA6, RHOU and SENP1 in mouse orthotopic tumor tissues and normal liver tissues (n = 3, left). Stained slides without the primary antibody were used as a negative control for IHC staining in HCC tissues. At least 6 randomly selected fields in the examined liver sections were measured in each group by the software Image Fiji (right). Scale bars, 20 μm. *P < 0.05; **P < 0.01; ***P < 0.001. (B) Representative immunohistochemical staining and quantitative results of AnxA6, RHOU and SENP1 in human HCC tissues and adjacent tissues (n = 3, left). Stained slides without the primary antibody were used as a negative control for IHC staining in HCC tissues. At least 6 randomly selected fields in the examined liver sections were measured in each group by software Image Fiji (right). Scale bar, 20 μm. *P < 0.05; **P < 0.01; ***P < 0.001. (C) AnxA6 downregulation in HCC tissues (n = 15) with different pathologic stages was validated by IHC (left). Quantitative results of AnxA6 in HCC tissues with different pathologic stages (right). *P < 0.05; **P < 0.01; ***P < 0.001. Scale bar, 20 μm. (D) The expression of AnxA6 in HCC tissues (n = 38) with different pathologic stages. *P < 0.05. ns, no statistical. (E) Low expression of ANXA6 in HCC was related to poor overall survival using Kaplan-Meier plotter database analysis. (F) High expression of SENP1 in HCC indicated poor overall survival. (G) The higher expression ratio of ANXA6/SENP1 indicated the higher survival rate of HCC patients. HR: hazard ratio. p-values were calculated using the log-rank test